Both neutralization resistance and high infectivity phenotypes are caused by mutations of interacting residues in the human immunodeficiency virus type 1 gp41 leucine zipper and the gp120 receptor- and coreceptor- binding domains

Journal of Virology

Volumn 73, Issue 7, 1999, Pages 5707-5713

  Park, Eun Ju ^a   Quinnan Jr , Gerald V ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; LEUCINE ZIPPER PROTEIN;

ARTICLE; GENE MUTATION; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; VIRUS ENVELOPE; VIRUS INFECTIVITY;

EID: 0345729871     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.73.7.5707-5713.1999     Document Type: Article

References (39)

1. Back, N. K. T., L. Smit, M. Schutten, P. L. Nara, M. Tersmette, and J. Goudsmit. 1993. Mutations in human immunodeficiency virus type 1 gp41 affect sensitivity to neutralization by gp120 antibodies. J. Virol. 47:6897-6902.
2. Chamat, S., P. Nara, L. Berquist, A. Whalley, W. J. M. Morrow, H. Kohler, and C.-Y. Kang. 1992. Two major groups of neutralizing anti-gp120 antibodies exist in HIV-infected individuals. J. Immunol. 149:645-654.
3. Chan, D. C., D. Fass, J. M. Berger, and P. S. Kim. 1997. Core structure of gp41 from the HIV envelope glycoprotein. Cell 89:263-273.
4. Chen, C.-H., T. J. Matthews, C. B. McDanal, D. P. Bolognasi, and M. L. Greenberg. 1995. A molecular clasp in the human immunodeficiency virus (HIV) type 1 TM protein determines the anti-HIV fusion activity of gp41 derivatives: implications for viral fusion. J. Virol. 69:3771-3777.
5. Conner, R. I., K. E. Sheridan, C. Lai, L. Zhang, and D. D. Ho. 1996. Characterization of the functional properties of env genes from long-term survivors of human immunodeficiency virus type 1 infection. J. Virol. 70: 5306-5311.
6. Delwart, E. L., G. Mosialos, and T. Gilmore. 1990. Retroviral envelope glycoproteins contain a leucine zipper-like repeat. AIDS Res. Hum. Retroviruses 6:703-706.
7. Hatch, W. C., K. E. Tanaka, T. Cavelli, W. K. Rashbaum, Y. Kress, and W. D. Lyman. 1992. Persistent productive HIV-1 infection of a CD4- human fetal thymocyte line. J. Immunol. 148:3055-3051.
8. Hendry, R. M., D. E. Parks, D. L. A. Campos Mello, G. V. Quinnan, and B. Galvao-Castro. 1991. Lack of evidence for HIV-2 infection among at-risk individualsin Brazil. J. Acquired Immune Defic. Syndr. 4:623-627.
9. Ho, D. D., M. S. C. Fung, Y. Cao, X. L. Li, C. Sun, T. W. Chang. 1991. Another discontinuous epitope on glycoprotein gp120 that is important in human immunodeficiency virus type 1 neutralization is identified by a monoclonal antibody. Proc. Natl. Acad. Sci. USA 88:8949-8952.
10. Ho, D., J. McKeating, X. Li, T. Moudgil, E. Daar, N.-C. Sun, and J. Robinson. 1991. Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody. J. Virol. 65:489-493.
11. Korber, B., S. Wolinsky, B. Haynes, K. Kunstman, R. Levy, M. Furtado, P. Otto, and G. Myers. 1992. HIV-1 intrapatient sequence diversity in the immunogenic V3 region. AIDS Res. Hum. Retroviruses 8:1461-1465.
12. Kwong, P. D., R. Wyatt, J. Robinson, R. W. Sweet, J. Sodroski, and W. A. Hendrickson. 1998. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393:648-659.
13. Lu, M., S. C. Blacklow, and P. S. Kim. 1995. A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat. Struct. Biol. 2:1075-1082.
14. Lu, M., and P. S. Kim. 1997. A trimeric structural subdomain of the HIV-1 transmembrane glycoprotein. J. Biomol. Struct. Dyn. 15:465-471.
15. McKeating, J. A., J. Gow, J. Goudsmit, L. H. Pearl, C. Mulder, and R. A. Weiss. 1989. Characterization of HIV-1 neutralization escape mutants. AIDS 3:777-784.
16. McKeating, J. A., C. Schotton, J. Cordell, S. Graham, P. Balfe, N. Sullivan, M. Charles, M. Page, A. Bolmstedt, S. Olofsson, S. C. Kayman, Z. Wu, A. Pinter, C. Dean, J. Sodroski, and R. A. Weiss. 1993. Characterization of neutralizing monoclonal antibodies to linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120. J. Virol. 67:4932-4944.
17. Moore, J. P., and D. D. Ho. 1993. Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans. J. Virol. 67:863-875.
18. Nara, P. L., L. Smit, N. Dunlop, W. Hatch, M. Merges, D. Waters, J. Kelliher, R. C. Gallo, P. J. Fischinger, and J. Goudsmit. 1990. Emergence of viruses resistant to neutralization by V3 specific antibodies in experimental human immunodeficiency virus type 1 IIIB infection of chimpanzees. J. Virol. 64:3779-3791.
19. O'Brien, W. A., I. S. Y. Chen, D. D. Ho, and E. S. Daar. 1992. Mapping genetic determinants for human immunodeficiency virus type 1 resistance to soluble CD4. J. Virol. 66:3125-3130.
20. Olshevsky, U., E. Helseth, C. Furman, J. Li, W. Haseltine, and J. Sodrowski. 1990. Identification of individual human immunodeficiency virus type 1 gp120 amino acids important for CD4 binding. J. Virol. 64:5701-5707.
21. Page, K. A., S. M. Stearns, and D. R. Littman. 1992. Analysis of mutations in the V3 domain of gp160 that affect fusion and infectivity. J. Virol. 66:524-533.
22. Park, E. J., L. K. Vujcic, R. Anand, T. S. Theodore, and G. V. Quinnan. 1998. Mutations in both gp120 and gp41 are responsible for the broad neutralization resistance of variant human immunodeficiency virus type 1 MN to antibodies directed at V3 and non-V3 epitopes. J. Virol. 72:7099-7107.
23. Quinnan, G. V., P. F. Zhang, D. W. Fu, M. Dong, and J. B. Margolick. 1998. Evolution of neutralizing antibody response against HIV type 1 virions and pseudovirions in multicenter AIDS cohort study participants. AIDS Res. Hum. Retroviruses 14:939-949.
24. Reitz, M. S., C. Wilson, C. Naugle, R. C. Gallo, and M. Robert-Guroff. 1988. Generation of a neutralization resistant variant of HIV-1 is due to selection for a point mutation in the envelope gene. Cell 54:57-63.
25. Rencher, S. D., K. S. Slobod, D. H. Dawson, T. D. Lockey, and J. L. Hurwitz. 1995. Does the key to a successful HIV type 1 vaccine lie among the envelope sequences of infected individuals? AIDS Res. Hum. Retroviruses 11:1131-1133.
26. Rizzuto, C. D., R. Wyatt, N. Hernandez-Ramos, Y. Sun, P. D. Kwong, W. A. Hendrickson, and J. Sodroski. 1998. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science 280:1949-1953.
27. Steimer, K. S., J. P. Puma, M. D. Power, M. A. Powers, C. George-Nascimento, J. C. Stephans, J. A. Levy, R. Sanchez-Pescador, P. A. Luciw, P. J. Barr, et al. 1986. Differential antibody responses of individuals infected with AIDS-associated retroviruses surveyed using the viral core antigen p25gag expressed in bacteria. Virology 150:283-290.
28. Steimer, K. S., J. Scandella, P. V. Skiles, and N. L. Haigwood. 1991. Neutralization of divergent HIV-1 isolates by conformation-dependent human antibodies to Gp120. Science 254:105-108.
29. Tan, K., J. Liu, J. Wang, S. Shen, and M. Lu. 1997. Atomic structure of a thermostable subdomain of HIV-1 gp41. Proc. Natl. Acad. Sci. USA 94: 12303-12308.
30. Thali, M., M. Charles, C. Furman, L. Cavacini, M. Posner, J. Robinson, and J. Sodroski. 1994. Resistance to neutralization by broadly reactive antibodies to the human immunodeficiency virus type 1 gp120 glycoprotein conferred by a gp41 amino acid change. J. Virol. 68:674-680.
31. Thali, M., J. P. Moore, C. Furman, M. Charlis, D. D. Ho, J. Robinson, and J. Sodroski. 1993. Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J. Virol. 67:3978-3988.
32. Vujcic, L. K., and G. V. Quinnan, Jr. 1995. Preparation and characterization of human HIV type 1 neutralizing reference sera. AIDS Res. Hum. Retroviruses 11:783-787.
33. Weissenhorn, W., A. Dessen, S. C. Harrison, J. J. Skehel, and D. C. Wiley. 1997. Atomic structure of the ectodomain from HIV-1 gp41. Nature 387: 426-430.
34. Weissenhorn, W., S. A. Wharton, L. J. Calder, P. L. Earl, B. Moss, E. Aliprandis, J. J. Skehel, and D. C. Wiley. 1996. The ectodomain of HIV-1 env subunit gp41 forms a soluble, alpha-helical, rod-like oligomer in the absence of gp120 and the N-terminal fusion peptide. EMBO J. 15:1507-1514.
35. Wild, C. T., D. C. Shugars, T. K. Greenwell, C. B. McDanal, and T. J. Matthews. 1994. Peptides corresponding to a predictive α-helical domain of human immunodeficiency virus type 1 are potent inhibitors of virus infection. Proc. Natl. Acad. Sci. USA 91:9770-9774.
36. Willey, R. L., E. K. Ross, A. J. Buckler-White, T. S. Theodore, and M. A. Martin. 1989. Functional interaction of constant and variable domains of human immunodeficiency virus type 1 gp120. J. Virol. 63:3595-3600.
37. Wittek, A. E., M. A. Phelan, M. A. Wells, L. K. Vujcic, J. S. Epstein, H. C. Lane, and G. V. Quinnan, Jr. 1987. Detection of human immunodeficiency virus core protein in plasma by enzyme immunoassay. Association of anti-genemia with symptomatic disease and T-helper cell depletion. Ann. Intern. Med. 107:286-292.
38. Wyatt, R., P. D. Kwong, E. Desjardins, R. W. Sweet, J. Robinson, W. A. Hendrickson, and J. G. Sodroski. 1998. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393:705-711.
39. Wyatt, R., and J. Sodroski. 1998. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 280:1884-1888.